Free Trial

Nu Skin Enterprises (NUS) Financials

Nu Skin Enterprises logo
$6.17 +0.01 (+0.16%)
Closing price 05/2/2025 03:59 PM Eastern
Extended Trading
$6.18 +0.01 (+0.24%)
As of 05/2/2025 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Nu Skin Enterprises

Annual Income Statements for Nu Skin Enterprises

This table shows Nu Skin Enterprises' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders
105 8.60 -147
Consolidated Net Income / (Loss)
105 8.60 -147
Net Income / (Loss) Continuing Operations
105 8.60 -147
Total Pre-Tax Income
89 27 -175
Total Operating Income
111 48 -152
Total Gross Profit
1,595 1,357 1,182
Total Revenue
2,226 1,969 1,732
Operating Revenue
2,226 1,969 1,732
Total Cost of Revenue
631 612 550
Operating Cost of Revenue
631 612 550
Total Operating Expenses
1,484 1,309 1,333
Selling, General & Admin Expense
1,435 1,289 1,131
Restructuring Charge
48 20 202
Total Other Income / (Expense), net
-22 -22 -23
Interest Expense
13 26 26
Other Income / (Expense), net
-8.38 3.87 2.94
Income Tax Expense
-16 18 -28
Basic Earnings per Share
$2.10 $0.17 ($2.95)
Weighted Average Basic Shares Outstanding
50.00M 49.71M 49.66M
Diluted Earnings per Share
$2.07 $0.17 ($2.95)
Weighted Average Diluted Shares Outstanding
50.53M 49.86M 49.66M
Weighted Average Basic & Diluted Shares Outstanding
49.46M 49.42M 49.72M

Quarterly Income Statements for Nu Skin Enterprises

This table shows Nu Skin Enterprises' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders
-25 57 11 27 -37 7.28 -0.53 -118 8.30 -36
Consolidated Net Income / (Loss)
-25 57 11 27 -37 7.28 -0.53 -118 8.30 -36
Net Income / (Loss) Continuing Operations
-25 57 11 27 -37 7.28 -0.53 -118 8.30 -36
Total Pre-Tax Income
-29 24 15 37 -34 9.33 1.10 -132 13 -58
Total Operating Income
-20 27 16 43 -26 16 8.82 -126 18 -53
Total Gross Profit
364 375 348 365 292 352 294 307 301 279
Total Revenue
538 522 481 500 499 489 417 439 430 446
Operating Revenue
538 522 481 500 499 489 417 439 430 446
Total Cost of Revenue
174 148 134 136 207 136 123 132 129 166
Operating Cost of Revenue
174 148 134 136 207 136 123 132 129 166
Total Operating Expenses
385 347 332 322 319 336 285 433 283 332
Selling, General & Admin Expense
354 329 322 322 319 326 278 283 283 286
Restructuring Charge
30 18 9.79 0.00 0.00 10 7.13 149 0.00 46
Total Other Income / (Expense), net
-8.68 -3.10 -1.48 -5.39 -8.09 -6.74 -7.72 -6.09 -4.93 -4.72
Interest Expense
- - 4.89 5.77 7.54 7.37 7.33 6.72 6.50 5.86
Other Income / (Expense), net
-8.68 10 3.41 0.38 -0.55 0.63 -0.40 0.63 1.57 1.14
Income Tax Expense
-3.57 -33 3.21 10 2.50 2.05 1.63 -13 5.00 -22
Basic Earnings per Share
($0.51) $1.16 $0.23 $0.54 ($0.74) $0.14 ($0.01) ($2.38) $0.17 ($0.73)
Weighted Average Basic Shares Outstanding
50.20M 50.00M 49.64M 49.93M 49.86M 49.71M 49.54M 49.69M 49.71M 49.66M
Diluted Earnings per Share
($0.51) $1.15 $0.23 $0.54 ($0.74) $0.14 ($0.01) ($2.38) $0.17 ($0.73)
Weighted Average Diluted Shares Outstanding
50.20M 50.53M 50.06M 50.16M 49.86M 49.86M 49.54M 49.69M 49.73M 49.66M
Weighted Average Basic & Diluted Shares Outstanding
49.42M 49.46M 49.91M 49.96M 49.41M 49.42M 49.67M 49.70M 49.71M 49.72M

Annual Cash Flow Statements for Nu Skin Enterprises

This table details how cash moves in and out of Nu Skin Enterprises' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents
-75 -8.67 -69
Net Cash From Operating Activities
108 119 112
Net Cash From Continuing Operating Activities
108 119 112
Net Income / (Loss) Continuing Operations
105 8.60 -147
Consolidated Net Income / (Loss)
105 8.60 -147
Depreciation Expense
73 71 70
Non-Cash Adjustments To Reconcile Net Income
118 139 272
Changes in Operating Assets and Liabilities, net
-188 -100 -84
Net Cash From Investing Activities
-67 -135 -38
Net Cash From Continuing Investing Activities
-67 -135 -38
Purchase of Property, Plant & Equipment
-59 -58 -42
Acquisitions
0.00 -77 0.00
Purchase of Investments
-14 -17 -15
Sale and/or Maturity of Investments
5.93 18 18
Net Cash From Financing Activities
-100 11 -133
Net Cash From Continuing Financing Activities
-100 11 -133
Repayment of Debt
-438 -13 -128
Repurchase of Common Equity
-70 -13 0.00
Payment of Dividends
-77 -78 -12
Issuance of Debt
460 110 15
Other Financing Activities, net
25 4.56 -8.36
Effect of Exchange Rate Changes
-16 -3.54 -9.78

Quarterly Cash Flow Statements for Nu Skin Enterprises

This table details how cash moves in and out of Nu Skin Enterprises' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents
-70 -29 -35 5.61 -2.24 23 -44 12 3.50 -41
Net Cash From Operating Activities
28 26 -22 36 51 54 3.32 51 31 26
Net Cash From Continuing Operating Activities
28 26 -22 36 51 54 3.32 51 31 26
Net Income / (Loss) Continuing Operations
-25 57 11 27 -37 7.28 -0.53 -118 8.30 -36
Consolidated Net Income / (Loss)
-25 57 11 27 -37 7.28 -0.53 -118 8.30 -36
Depreciation Expense
18 19 17 17 18 19 18 18 17 16
Non-Cash Adjustments To Reconcile Net Income
65 20 14 26 83 17 16 160 14 83
Changes in Operating Assets and Liabilities, net
-29 -71 -64 -34 -13 11 -31 -7.66 -7.96 -38
Net Cash From Investing Activities
-25 -13 -15 -93 -12 -15 -9.26 -8.53 -6.55 -14
Net Cash From Continuing Investing Activities
-25 -13 -15 -93 -12 -15 -9.26 -8.53 -6.55 -14
Purchase of Property, Plant & Equipment
-25 -14 -11 -15 -12 -20 -12 -8.12 -8.60 -13
Purchase of Investments
- - -8.20 -8.69 - - 0.00 -8.57 -5.15 -1.04
Net Cash From Financing Activities
-61 -51 1.38 68 -38 -20 -32 -29 -29 -44
Net Cash From Continuing Financing Activities
-61 -51 1.38 68 -38 -20 -32 -29 -29 -44
Repayment of Debt
-2.50 -23 -2.50 -4.05 -3.45 -3.20 -20 -25 -40 -43
Payment of Dividends
-19 -19 -19 -19 -19 -19 -2.98 -2.98 -2.98 -2.98
Other Financing Activities, net
0.72 0.74 3.27 1.51 -2.42 2.20 -8.98 -0.84 -0.80 2.24
Effect of Exchange Rate Changes
-12 9.24 - - -2.99 4.24 - - 7.39 -9.41

Annual Balance Sheets for Nu Skin Enterprises

This table presents Nu Skin Enterprises' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets
1,821 1,809 1,469
Total Current Assets
760 702 539
Cash & Equivalents
265 256 187
Short-Term Investments
14 12 11
Accounts Receivable
47 59 51
Inventories, net
346 280 190
Prepaid Expenses
88 81 73
Other Current Nonoperating Assets
- 14 27
Plant, Property, & Equipment, net
445 433 380
Total Noncurrent Assets
616 674 551
Goodwill
206 218 84
Intangible Assets
67 95 74
Other Noncurrent Operating Assets
343 338 371
Other Noncurrent Nonoperating Assets
- 23 22
Total Liabilities & Shareholders' Equity
1,821 1,809 1,469
Total Liabilities
924 987 817
Total Current Liabilities
359 329 297
Short-Term Debt
25 25 30
Accounts Payable
54 43 35
Accrued Expenses
280 254 218
Other Current Nonoperating Liabilities
- 7.06 14
Total Noncurrent Liabilities
564 658 521
Long-Term Debt
377 478 364
Other Noncurrent Operating Liabilities
187 178 156
Other Noncurrent Nonoperating Liabilities
- 2.16 1.33
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
897 822 651
Total Preferred & Common Equity
897 822 651
Total Common Equity
897 822 651
Common Stock
613 622 628
Retained Earnings
1,939 1,870 1,712
Treasury Stock
-1,569 -1,570 -1,564
Accumulated Other Comprehensive Income / (Loss)
-87 -100 -125

Quarterly Balance Sheets for Nu Skin Enterprises

This table presents Nu Skin Enterprises' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets
1,763 1,825 1,894 1,793 1,742 1,586 1,583
Total Current Assets
778 774 793 701 647 654 653
Cash & Equivalents
294 230 236 233 213 224 228
Short-Term Investments
14 17 17 17 8.67 8.67 10
Accounts Receivable
48 60 67 77 67 72 69
Inventories, net
327 367 372 291 265 244 248
Prepaid Expenses
94 100 101 83 94 106 99
Plant, Property, & Equipment, net
433 438 430 429 423 412 411
Total Noncurrent Assets
552 613 671 663 672 520 519
Goodwill
206 206 229 229 231 100 100
Intangible Assets
69 65 113 109 102 88 85
Other Noncurrent Operating Assets
277 342 329 325 339 331 334
Total Liabilities & Shareholders' Equity
1,763 1,825 1,894 1,793 1,742 1,586 1,583
Total Liabilities
921 932 998 971 932 900 876
Total Current Liabilities
366 373 445 434 309 309 339
Short-Term Debt
43 48 140 140 30 30 60
Accounts Payable
42 49 50 49 32 36 33
Accrued Expenses
281 276 256 245 247 242 247
Total Noncurrent Liabilities
556 559 553 537 622 591 537
Long-Term Debt
382 373 368 363 453 428 373
Other Noncurrent Operating Liabilities
173 186 186 174 169 163 163
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
842 893 895 822 810 686 707
Total Preferred & Common Equity
842 893 895 822 810 686 707
Total Common Equity
842 893 895 822 810 686 707
Common Stock
610 612 616 619 619 622 625
Retained Earnings
1,901 1,931 1,939 1,882 1,867 1,746 1,751
Treasury Stock
-1,560 -1,559 -1,558 -1,571 -1,565 -1,564 -1,564
Accumulated Other Comprehensive Income / (Loss)
-109 -91 -101 -109 -111 -117 -105

Annual Metrics and Ratios for Nu Skin Enterprises

This table displays calculated financial ratios and metrics derived from Nu Skin Enterprises' official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics
- - -
Revenue Growth
-17.44% -11.53% -12.04%
EBITDA Growth
-43.34% -29.67% -164.06%
EBIT Growth
-55.92% -49.12% -385.09%
NOPAT Growth
-11.94% -88.04% -779.78%
Net Income Growth
-28.85% -91.80% -1,805.57%
EPS Growth
-27.62% -91.79% -1,835.29%
Operating Cash Flow Growth
-23.68% 9.79% -5.81%
Free Cash Flow Firm Growth
120.25% -82.96% 1,384.93%
Invested Capital Growth
9.31% 0.80% -21.01%
Revenue Q/Q Growth
-6.36% -1.68% -2.43%
EBITDA Q/Q Growth
12.56% -5.85% -134.46%
EBIT Q/Q Growth
23.38% -12.81% -40.80%
NOPAT Q/Q Growth
172.72% -81.40% -83.87%
Net Income Q/Q Growth
173.34% -85.31% -42.04%
EPS Q/Q Growth
176.00% -85.59% -41.83%
Operating Cash Flow Q/Q Growth
-43.73% 31.83% -20.25%
Free Cash Flow Firm Q/Q Growth
-61.33% 122.89% -4.10%
Invested Capital Q/Q Growth
6.52% -4.25% -9.90%
Profitability Metrics
- - -
Gross Margin
71.65% 68.93% 68.23%
EBITDA Margin
7.86% 6.25% -4.55%
Operating Margin
4.98% 2.45% -8.75%
EBIT Margin
4.60% 2.65% -8.58%
Profit (Net Income) Margin
4.71% 0.44% -8.46%
Tax Burden Percent
117.77% 32.34% 83.74%
Interest Burden Percent
86.83% 50.98% 117.77%
Effective Tax Rate
-17.77% 67.66% 0.00%
Return on Invested Capital (ROIC)
13.35% 1.52% -11.52%
ROIC Less NNEP Spread (ROIC-NNEP)
-22.08% -2.71% -33.45%
Return on Net Nonoperating Assets (RNNOA)
-1.77% -0.52% -8.38%
Return on Equity (ROE)
11.58% 1.00% -19.90%
Cash Return on Invested Capital (CROIC)
4.45% 0.72% 11.96%
Operating Return on Assets (OROA)
5.50% 2.87% -9.07%
Return on Assets (ROA)
5.62% 0.47% -8.95%
Return on Common Equity (ROCE)
11.58% 1.00% -19.90%
Return on Equity Simple (ROE_SIMPLE)
11.68% 1.05% -22.50%
Net Operating Profit after Tax (NOPAT)
131 16 -106
NOPAT Margin
5.87% 0.79% -6.13%
Net Nonoperating Expense Percent (NNEP)
35.43% 4.23% 21.93%
Return On Investment Capital (ROIC_SIMPLE)
10.04% 1.18% -10.15%
Cost of Revenue to Revenue
28.35% 31.07% 31.77%
SG&A Expenses to Revenue
64.49% 65.47% 65.30%
R&D to Revenue
0.00% 0.00% 0.00%
Operating Expenses to Revenue
66.67% 66.48% 76.98%
Earnings before Interest and Taxes (EBIT)
102 52 -149
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
175 123 -79
Valuation Ratios
- - -
Price to Book Value (P/BV)
2.13 1.14 0.53
Price to Tangible Book Value (P/TBV)
3.07 1.84 0.69
Price to Revenue (P/Rev)
0.86 0.48 0.20
Price to Earnings (P/E)
18.28 109.01 0.00
Dividend Yield
3.97% 8.23% 3.48%
Earnings Yield
5.47% 0.92% 0.00%
Enterprise Value to Invested Capital (EV/IC)
2.00 1.14 0.66
Enterprise Value to Revenue (EV/Rev)
0.92 0.60 0.31
Enterprise Value to EBITDA (EV/EBITDA)
11.66 9.53 0.00
Enterprise Value to EBIT (EV/EBIT)
19.90 22.48 0.00
Enterprise Value to NOPAT (EV/NOPAT)
15.62 75.10 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
18.87 9.88 4.82
Enterprise Value to Free Cash Flow (EV/FCFF)
46.85 158.02 4.89
Leverage & Solvency
- - -
Debt to Equity
0.45 0.61 0.60
Long-Term Debt to Equity
0.42 0.58 0.56
Financial Leverage
0.08 0.19 0.25
Leverage Ratio
2.06 2.11 2.22
Compound Leverage Factor
1.79 1.08 2.62
Debt to Total Capital
30.96% 37.97% 37.66%
Short-Term Debt to Total Capital
1.92% 1.89% 2.87%
Long-Term Debt to Total Capital
29.04% 36.08% 34.79%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
69.04% 62.03% 62.34%
Debt to EBITDA
2.30 4.09 -4.99
Net Debt to EBITDA
0.71 1.91 -2.48
Long-Term Debt to EBITDA
2.16 3.88 -4.61
Debt to NOPAT
3.08 32.23 -3.71
Net Debt to NOPAT
0.95 15.07 -1.84
Long-Term Debt to NOPAT
2.89 30.63 -3.43
Altman Z-Score
4.41 3.45 2.93
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
2.12 2.13 1.82
Quick Ratio
0.91 0.99 0.84
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
44 7.42 110
Operating Cash Flow to CapEx
182.98% 202.84% 268.72%
Free Cash Flow to Firm to Interest Expense
3.23 0.29 4.17
Operating Cash Flow to Interest Expense
8.01 4.64 4.23
Operating Cash Flow Less CapEx to Interest Expense
3.63 2.35 2.66
Efficiency Ratios
- - -
Asset Turnover
1.19 1.09 1.06
Accounts Receivable Turnover
50.21 37.13 31.64
Inventory Turnover
1.69 1.95 2.34
Fixed Asset Turnover
4.95 4.49 4.26
Accounts Payable Turnover
12.14 12.61 14.11
Days Sales Outstanding (DSO)
7.27 9.83 11.54
Days Inventory Outstanding (DIO)
215.82 186.77 155.96
Days Payable Outstanding (DPO)
30.07 28.96 25.87
Cash Conversion Cycle (CCC)
193.02 167.64 141.63
Capital & Investment Metrics
- - -
Invested Capital
1,021 1,029 813
Invested Capital Turnover
2.28 1.92 1.88
Increase / (Decrease) in Invested Capital
87 8.19 -216
Enterprise Value (EV)
2,039 1,172 538
Market Capitalization
1,915 937 343
Book Value per Share
$18.16 $16.64 $13.10
Tangible Book Value per Share
$12.63 $10.29 $9.93
Total Capital
1,300 1,325 1,045
Total Debt
402 503 394
Total Long-Term Debt
377 478 364
Net Debt
124 235 196
Capital Expenditures (CapEx)
59 58 42
Debt-free, Cash-free Net Working Capital (DFCFNWC)
147 130 74
Debt-free Net Working Capital (DFNWC)
426 398 272
Net Working Capital (NWC)
401 373 242
Net Nonoperating Expense (NNE)
26 7.01 40
Net Nonoperating Obligations (NNO)
124 207 162
Total Depreciation and Amortization (D&A)
73 71 70
Debt-free, Cash-free Net Working Capital to Revenue
6.61% 6.61% 4.27%
Debt-free Net Working Capital to Revenue
19.12% 20.21% 15.70%
Net Working Capital to Revenue
18.00% 18.94% 13.97%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
$2.10 $0.17 ($2.95)
Adjusted Weighted Average Basic Shares Outstanding
50.00M 49.71M 49.66M
Adjusted Diluted Earnings per Share
$2.07 $0.17 ($2.95)
Adjusted Weighted Average Diluted Shares Outstanding
50.53M 49.86M 49.66M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
49.46M 49.42M 49.72M
Normalized Net Operating Profit after Tax (NOPAT)
112 48 36
Normalized NOPAT Margin
5.01% 2.42% 2.05%
Pre Tax Income Margin
4.00% 1.35% -10.11%
Debt Service Ratios
- - -
EBIT to Interest Expense
7.59 2.04 -5.63
NOPAT to Interest Expense
9.67 0.61 -4.02
EBIT Less CapEx to Interest Expense
3.22 -0.25 -7.20
NOPAT Less CapEx to Interest Expense
5.30 -1.68 -5.59
Payout Ratios
- - -
Dividend Payout Ratio
73.50% 903.11% -8.14%
Augmented Payout Ratio
140.35% 1,054.49% -8.14%

Quarterly Metrics and Ratios for Nu Skin Enterprises

This table displays calculated financial ratios and metrics derived from Nu Skin Enterprises' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
-16.12% -22.44% -20.41% -10.77% -7.26% -6.45% -13.33% -12.23% -13.76% -8.82%
EBITDA Growth
-112.25% 52.91% -46.24% -2.40% 19.17% -37.47% -26.32% -278.74% 525.48% -200.59%
EBIT Growth
-142.49% 105.31% -61.58% -0.01% 7.07% -55.89% -56.74% -391.33% 173.55% -411.08%
NOPAT Growth
-129.77% 734.01% -68.55% -25.12% -29.98% -80.56% -134.09% -385.36% 161.67% -396.31%
Net Income Growth
-151.06% 719.81% -70.62% -21.45% -45.55% -87.27% -104.69% -539.75% 122.47% -595.81%
EPS Growth
-152.58% 776.47% -69.74% -19.40% -45.10% -87.83% -104.35% -540.74% 122.97% -621.43%
Operating Cash Flow Growth
-5.87% -76.69% -392.76% -23.70% 79.41% 112.21% 115.03% 44.16% -38.40% -52.40%
Free Cash Flow Firm Growth
127.50% 83.77% -39.24% -491.31% -367.00% 119.32% 85.20% 213.29% 236.47% 4,018.64%
Invested Capital Growth
-6.32% 9.31% 8.19% 16.66% 12.13% 0.80% 0.55% -20.79% -16.05% -21.01%
Revenue Q/Q Growth
-4.07% -2.88% -7.83% 3.90% -0.30% -2.03% -14.60% 5.22% -2.04% 3.58%
EBITDA Q/Q Growth
-117.54% 622.74% -15.07% 64.69% -114.53% 504.40% 55.68% -499.53% 134.59% -195.61%
EBIT Q/Q Growth
-167.54% 230.67% -20.03% 120.18% -162.77% 162.03% 734.01% -1,582.65% 115.85% -362.34%
NOPAT Q/Q Growth
-134.52% 554.31% -80.58% 145.87% -159.92% 167.95% -134.06% -1,957.94% 112.95% -426.46%
Net Income Q/Q Growth
-174.16% 325.34% -80.12% 136.39% -237.42% 119.71% -107.32% -22,087.24% 107.02% -534.90%
EPS Q/Q Growth
-176.12% 325.49% -80.00% 134.78% -237.04% 118.92% -107.14% -23,700.00% 107.14% -529.41%
Operating Cash Flow Q/Q Growth
-38.91% -10.25% -186.49% 260.90% 43.65% 6.15% -93.87% 1,443.31% -38.62% -17.97%
Free Cash Flow Firm Q/Q Growth
47.92% -144.58% -202.89% -95.92% -0.93% 103.23% 56.88% 1,599.66% 21.58% -2.64%
Invested Capital Q/Q Growth
-2.80% 6.52% 4.42% 7.92% -6.58% -4.25% 1.42% -14.98% -0.99% -9.90%
Profitability Metrics
- - - - - - - - - -
Gross Margin
67.74% 71.70% 72.25% 72.91% 58.60% 72.12% 70.47% 69.96% 70.08% 62.65%
EBITDA Margin
-2.01% 10.80% 7.57% 12.00% -1.75% 7.22% 6.44% -24.44% 8.63% -7.97%
Operating Margin
-3.77% 5.26% 3.34% 8.50% -5.29% 3.29% 2.11% -28.60% 4.24% -11.91%
EBIT Margin
-5.39% 7.25% 4.05% 8.57% -5.40% 3.42% 2.02% -28.45% 4.60% -11.66%
Profit (Net Income) Margin
-4.72% 10.95% 2.36% 5.38% -7.41% 1.49% -0.13% -26.93% 1.93% -8.10%
Tax Burden Percent
87.66% 234.92% 77.98% 72.46% 107.27% 78.07% -48.41% 89.83% 62.43% 62.46%
Interest Burden Percent
100.00% 64.35% 74.90% 86.55% 127.99% 55.87% 13.07% 105.38% 67.17% 111.29%
Effective Tax Rate
0.00% -134.92% 22.02% 27.54% 0.00% 21.93% 148.41% 0.00% 37.57% 0.00%
Return on Invested Capital (ROIC)
-6.33% 28.11% 5.33% 11.76% -7.29% 4.93% -1.82% -35.79% 4.75% -15.68%
ROIC Less NNEP Spread (ROIC-NNEP)
-17.32% 18.08% 4.31% 9.17% -17.29% 1.76% -0.11% -48.42% 3.38% -15.11%
Return on Net Nonoperating Assets (RNNOA)
-1.98% 1.45% 0.53% 1.50% -3.84% 0.34% -0.03% -14.72% 0.99% -3.79%
Return on Equity (ROE)
-8.32% 29.56% 5.86% 13.27% -11.13% 5.27% -1.85% -50.51% 5.74% -19.46%
Cash Return on Invested Capital (CROIC)
11.36% 4.45% 2.81% -6.22% -3.19% 0.72% -1.52% 14.57% 11.62% 11.96%
Operating Return on Assets (OROA)
-6.85% 8.65% 4.58% 9.22% -6.08% 3.71% 2.16% -30.15% 4.84% -12.32%
Return on Assets (ROA)
-6.00% 13.08% 2.67% 5.79% -8.35% 1.62% -0.14% -28.54% 2.03% -8.56%
Return on Common Equity (ROCE)
-8.32% 29.56% 5.86% 13.27% -11.13% 5.27% -1.85% -50.51% 5.74% -19.46%
Return on Equity Simple (ROE_SIMPLE)
4.55% 0.00% 8.67% 7.83% 7.12% 0.00% -0.41% -21.64% -14.60% 0.00%
Net Operating Profit after Tax (NOPAT)
-14 65 13 31 -18 13 -4.27 -88 11 -37
NOPAT Margin
-2.64% 12.35% 2.60% 6.16% -3.70% 2.57% -1.02% -20.02% 2.65% -8.34%
Net Nonoperating Expense Percent (NNEP)
10.98% 10.03% 1.02% 2.60% 10.01% 3.17% -1.72% 12.63% 1.37% -0.57%
Return On Investment Capital (ROIC_SIMPLE)
- 4.96% - - - 0.95% - - - -3.56%
Cost of Revenue to Revenue
32.26% 28.30% 27.75% 27.09% 41.40% 27.88% 29.53% 30.04% 29.92% 37.35%
SG&A Expenses to Revenue
65.91% 62.93% 66.88% 64.41% 63.88% 66.79% 66.64% 64.54% 65.85% 64.27%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
71.51% 66.44% 68.92% 64.41% 63.88% 68.84% 68.35% 98.55% 65.85% 74.57%
Earnings before Interest and Taxes (EBIT)
-29 38 19 43 -27 17 8.43 -125 20 -52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-11 56 36 60 -8.72 35 27 -107 37 -35
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
1.84 2.13 2.05 1.76 1.24 1.14 0.84 0.76 0.52 0.53
Price to Tangible Book Value (P/TBV)
2.74 3.07 2.94 2.85 2.11 1.84 1.42 1.05 0.70 0.69
Price to Revenue (P/Rev)
0.65 0.86 0.87 0.77 0.51 0.48 0.36 0.28 0.21 0.20
Price to Earnings (P/E)
40.50 18.28 23.64 22.51 17.41 109.01 0.00 0.00 0.00 0.00
Dividend Yield
4.98% 3.97% 4.17% 4.90% 7.62% 8.23% 8.93% 8.54% 7.73% 3.48%
Earnings Yield
2.47% 5.47% 4.23% 4.44% 5.74% 0.92% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.74 2.00 1.88 1.59 1.18 1.14 0.88 0.82 0.62 0.66
Enterprise Value to Revenue (EV/Rev)
0.70 0.92 0.95 0.90 0.64 0.60 0.49 0.41 0.32 0.31
Enterprise Value to EBITDA (EV/EBITDA)
10.74 11.66 15.40 14.25 9.73 9.53 10.72 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
20.10 19.90 34.70 31.74 21.27 22.48 60.68 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
34.87 15.62 18.30 18.73 15.16 75.10 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
8.69 18.87 25.54 27.19 14.14 9.88 6.54 4.69 4.01 4.82
Enterprise Value to Free Cash Flow (EV/FCFF)
14.83 46.85 69.53 0.00 0.00 158.02 0.00 4.98 4.89 4.89
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.50 0.45 0.47 0.57 0.61 0.61 0.60 0.67 0.61 0.60
Long-Term Debt to Equity
0.45 0.42 0.42 0.41 0.44 0.58 0.56 0.62 0.53 0.56
Financial Leverage
0.11 0.08 0.12 0.16 0.22 0.19 0.26 0.30 0.29 0.25
Leverage Ratio
2.10 2.06 2.03 2.07 2.14 2.11 2.09 2.20 2.21 2.22
Compound Leverage Factor
2.10 1.33 1.52 1.79 2.74 1.18 0.27 2.32 1.48 2.48
Debt to Total Capital
33.54% 30.96% 31.99% 36.19% 37.95% 37.97% 37.36% 40.05% 38.01% 37.66%
Short-Term Debt to Total Capital
3.36% 1.92% 3.62% 9.98% 10.57% 1.89% 2.32% 2.62% 5.26% 2.87%
Long-Term Debt to Total Capital
30.18% 29.04% 28.38% 26.21% 27.39% 36.08% 35.04% 37.43% 32.75% 34.79%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
66.46% 69.04% 68.01% 63.81% 62.05% 62.03% 62.64% 59.95% 61.99% 62.34%
Debt to EBITDA
2.73 2.30 3.23 3.95 3.85 4.09 5.50 -5.77 -12.89 -4.99
Net Debt to EBITDA
0.75 0.71 1.33 1.99 1.93 1.91 2.98 -2.84 -5.82 -2.48
Long-Term Debt to EBITDA
2.46 2.16 2.86 2.86 2.78 3.88 5.16 -5.39 -11.11 -4.61
Debt to NOPAT
8.88 3.08 3.84 5.19 5.99 32.23 -46.52 -5.15 -7.51 -3.71
Net Debt to NOPAT
2.44 0.95 1.58 2.61 3.01 15.07 -25.22 -2.53 -3.39 -1.84
Long-Term Debt to NOPAT
7.99 2.89 3.40 3.76 4.32 30.63 -43.64 -4.82 -6.47 -3.43
Altman Z-Score
4.10 4.29 4.11 3.75 3.35 3.38 3.28 3.05 3.20 3.14
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
2.13 2.12 2.08 1.78 1.62 2.13 2.09 2.12 1.93 1.82
Quick Ratio
0.97 0.91 0.82 0.72 0.75 0.99 0.93 0.99 0.90 0.84
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
50 -23 -68 -134 -135 4.35 -10 151 184 179
Operating Cash Flow to CapEx
111.73% 185.21% -192.19% 241.45% 428.58% 265.72% 27.02% 630.40% 365.66% 204.92%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 -13.95 -23.15 -17.89 0.59 -1.38 22.52 28.30 30.54
Operating Cash Flow to Interest Expense
0.00 0.00 -4.52 6.16 6.77 7.35 0.45 7.62 4.84 4.40
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 -6.87 3.61 5.19 4.59 -1.22 6.41 3.51 2.25
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
1.27 1.19 1.13 1.08 1.13 1.09 1.07 1.06 1.05 1.06
Accounts Receivable Turnover
47.33 50.21 37.48 36.84 31.98 37.13 29.99 26.58 24.31 31.64
Inventory Turnover
1.77 1.69 1.61 1.63 2.02 1.95 1.90 1.94 1.93 2.34
Fixed Asset Turnover
5.30 4.95 4.74 4.68 4.65 4.49 4.43 4.38 4.23 4.26
Accounts Payable Turnover
14.03 12.14 13.37 11.30 13.82 12.61 14.72 13.93 12.79 14.11
Days Sales Outstanding (DSO)
7.71 7.27 9.74 9.91 11.41 9.83 12.17 13.73 15.02 11.54
Days Inventory Outstanding (DIO)
206.34 215.82 226.42 224.54 181.08 186.77 191.64 188.11 189.11 155.96
Days Payable Outstanding (DPO)
26.02 30.07 27.30 32.31 26.40 28.96 24.80 26.20 28.54 25.87
Cash Conversion Cycle (CCC)
188.04 193.02 208.86 202.14 166.08 167.64 179.02 175.64 175.59 141.63
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
959 1,021 1,066 1,151 1,075 1,029 1,072 912 903 813
Invested Capital Turnover
2.40 2.28 2.05 1.91 1.97 1.92 1.78 1.79 1.80 1.88
Increase / (Decrease) in Invested Capital
-65 87 81 164 116 8.19 5.82 -239 -173 -216
Enterprise Value (EV)
1,669 2,039 2,004 1,833 1,272 1,172 942 749 562 538
Market Capitalization
1,552 1,915 1,830 1,577 1,019 937 680 523 366 343
Book Value per Share
$16.71 $18.16 $18.05 $17.94 $16.46 $16.64 $16.36 $13.82 $14.22 $13.10
Tangible Book Value per Share
$11.25 $12.63 $12.57 $11.09 $9.68 $10.29 $9.64 $10.02 $10.50 $9.93
Total Capital
1,267 1,300 1,313 1,403 1,325 1,325 1,293 1,144 1,140 1,045
Total Debt
425 402 420 508 503 503 483 458 433 394
Total Long-Term Debt
382 377 373 368 363 478 453 428 373 364
Net Debt
117 124 173 255 253 235 262 225 196 196
Capital Expenditures (CapEx)
25 14 11 15 12 20 12 8.12 8.60 13
Debt-free, Cash-free Net Working Capital (DFCFNWC)
147 147 202 235 157 130 147 143 136 74
Debt-free Net Working Capital (DFNWC)
455 426 448 488 407 398 368 376 374 272
Net Working Capital (NWC)
412 401 401 348 267 373 338 346 314 242
Net Nonoperating Expense (NNE)
11 7.29 1.15 3.91 18 5.26 -3.74 30 3.08 -1.05
Net Nonoperating Obligations (NNO)
117 124 173 255 253 207 262 225 196 162
Total Depreciation and Amortization (D&A)
18 19 17 17 18 19 18 18 17 16
Debt-free, Cash-free Net Working Capital to Revenue
6.18% 6.61% 9.59% 11.52% 7.84% 6.61% 7.70% 7.75% 7.67% 4.27%
Debt-free Net Working Capital to Revenue
19.14% 19.12% 21.32% 23.88% 20.33% 20.21% 19.32% 20.38% 21.07% 15.70%
Net Working Capital to Revenue
17.35% 18.00% 19.07% 17.02% 13.34% 18.94% 17.74% 18.76% 17.69% 13.97%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.51) $1.16 $0.23 $0.54 ($0.74) $0.14 ($0.01) ($2.38) $0.17 ($0.73)
Adjusted Weighted Average Basic Shares Outstanding
50.20M 50.00M 49.64M 49.93M 49.86M 49.71M 49.54M 49.69M 49.71M 49.66M
Adjusted Diluted Earnings per Share
($0.51) $1.15 $0.23 $0.54 ($0.74) $0.14 ($0.01) ($2.38) $0.17 ($0.73)
Adjusted Weighted Average Diluted Shares Outstanding
50.20M 50.53M 50.06M 50.16M 49.86M 49.86M 49.54M 49.69M 49.73M 49.66M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
49.42M 49.46M 49.91M 49.96M 49.41M 49.42M 49.67M 49.70M 49.71M 49.72M
Normalized Net Operating Profit after Tax (NOPAT)
6.89 32 20 31 -18 20 11 17 11 -5.04
Normalized NOPAT Margin
1.28% 6.14% 4.19% 6.16% -3.70% 4.16% 2.68% 3.79% 2.65% -1.13%
Pre Tax Income Margin
-5.39% 4.66% 3.03% 7.42% -6.91% 1.91% 0.26% -29.98% 3.09% -12.97%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 3.98 7.43 -3.57 2.27 1.15 -18.59 3.05 -8.86
NOPAT to Interest Expense
0.00 0.00 2.56 5.34 -2.45 1.70 -0.58 -13.08 1.75 -6.34
EBIT Less CapEx to Interest Expense
0.00 0.00 1.63 4.88 -5.15 -0.50 -0.53 -19.80 1.72 -11.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.21 2.79 -4.03 -1.06 -2.26 -14.29 0.43 -8.48
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
200.68% 73.50% 99.58% 110.14% 132.21% 903.11% -1,846.98% -30.12% -27.34% -8.14%
Augmented Payout Ratio
383.41% 140.35% 99.58% 110.14% 171.54% 1,054.49% -1,846.98% -30.12% -27.34% -8.14%

Frequently Asked Questions About Nu Skin Enterprises' Financials

When does Nu Skin Enterprises's fiscal year end?

According to the most recent income statement we have on file, Nu Skin Enterprises' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Nu Skin Enterprises' net income changed over the last 2 years?

Nu Skin Enterprises' net income appears to be on an upward trend, with a most recent value of -$146.59 million in 2024, falling from $104.78 million in 2022. The previous period was $8.60 million in 2023. Check out Nu Skin Enterprises' forecast to explore projected trends and price targets.

What is Nu Skin Enterprises's operating income?
Nu Skin Enterprises's total operating income in 2024 was -$151.59 million, based on the following breakdown:
  • Total Gross Profit: $1.18 billion
  • Total Operating Expenses: $1.33 billion
How has Nu Skin Enterprises revenue changed over the last 2 years?

Over the last 2 years, Nu Skin Enterprises' total revenue changed from $2.23 billion in 2022 to $1.73 billion in 2024, a change of -22.2%.

How much debt does Nu Skin Enterprises have?

Nu Skin Enterprises' total liabilities were at $817.46 million at the end of 2024, a 17.1% decrease from 2023, and a 11.5% decrease since 2022.

How much cash does Nu Skin Enterprises have?

In the past 2 years, Nu Skin Enterprises' cash and equivalents has ranged from $186.88 million in 2024 to $264.73 million in 2022, and is currently $186.88 million as of their latest financial filing in 2024.

How has Nu Skin Enterprises' book value per share changed over the last 2 years?

Over the last 2 years, Nu Skin Enterprises' book value per share changed from 18.16 in 2022 to 13.10 in 2024, a change of -27.8%.



This page (NYSE:NUS) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners